GEN-MKT-18-7897-A
Oct 11, 2017 | Blogs, Technology | 0 comments
If you are working with complex assays that demand exceptionally selective quantitative and qualitative performance, sometimes even the most powerful LC-MS/MS technology can’t always cut it alone.
Perhaps you are struggling to separate isobaric species, isolate challenging co-eluting analytes or reduce high background noise? Regardless of your challenge, the outcome is the same. You probably aren’t getting the levels of quantitation or characterization you need, so method development has become cumbersome, and workflow performance is suffering.
Now you can bring a new dimension of selectivity to your LC-MS/MS analysis on select SCIEX Triple Quad™, QTRAP® and TripleTOF® Systems with SelexION® Differential Mobility Separation (DMS) Technology. The SelexION DMS cell:
Harness the power of differential mobility separations to simplify your sample preparations, while achieving unprecedented levels of selectivity. Find out more by downloading the SelexION brochure.
How does it work?Gas phase differential mobility separation within the SelexION device planar mobility cell is based on the ion’s size and shape, and the difference between their unique differential mobilities across high and low energy fields. Gas phase separation occurs prior to entering the mass analyzer where the compounds are then further separated by m/z ratios.
Ultra‑low reporting limits, expanding target lists, and the constant risk of background contamination mean that even small missteps before injection can compromise data integrity. PFAS can be introduced at nearly every stage of prep, from sampling containers and PPE to SPE cartridges, filters, solvents, and lab consumables, making contamination control as critical as analyte recovery.
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
Posted by
You must be logged in to post a comment.
Share this post with your network